Stemrim Inc. · TSE:4599
Stemrim — Investor Presentation (October 2026)
58 slides from Stemrim's investor presentation, Oct 30, 2026
Slide 1: Presentation Material for Business Plan and Growth Potential
sts Presentation Material for Business Plan and Growth Potential StemRIM Inc. (Stock code: TSE4599) October 30,2026 ©2 stemnim
Slide 2: PURPOSE: Empower Life Regeneration
PURPOSE Empower Life Regeneration.
Slide 3: 1. Business Model and R&D Structure
1. Business Model and R&D Structure
Slide 4: Business Model
Business Model A business model that generates income by licensing out product development, manufacturing, and marketing rights to pharmaceutical companies in Japan and overseas. About a 10-15 years development period until the launch of pharmaceutical products Discovery/ catered Non-clinical Clinic
Slide 5: Main Contracts with Pharmaceutical Companies
Main Contracts with Pharmaceutical Companies Contract Name (Date of Agreement) CoatbAoy Implementation License Shionogi & Agreement(November 2014) Co. Ltd. Contract for the accelerated clinical | Shionogi & development of the “Regeneration- Co, Ltd. Inducing Medicine™ "candidate Redasemtide for mult
Slide 6: FY2026 financial results
2026 7A RAZ *For FY 2026, there were no recognition of milestone revenues related to research progress or upfront payments from contracts. As a result, operating revenue was none. Since we are a drug discovery bio- venture, we have an unstable revenue structure considering our business model. ‘As of
Slide 7: Katsuto Tamai, Representative Director, Chairman and CSO
Katsuto Tamai, our current Representative Director , Chairman and Chief Scientific Officer (CSO), was inspired to explore the potential of skin regeneration using bone marrow-derived stem cells after encountering a patient with the rare and debilitating disease, Dystrophic Epidermolysis Bullosa. He
Slide 8: Research and Development system
Research and Development system At Stemrim, in collaboration with Osaka University and the Institute for Advanced Co-Creation Studies in “Regeneration- Inducing Medicine™”, we are comprehensively promoting OSAKA UNIVERSITY the entire research and development process toward the | ‘Basic Research in -
Slide 9: 2. Mechanism of Action
2. Mechanism of Action of
Slide 10: Mechanism of Action of Regeneration-Inducing Medicine
Mechanism of Action of “Regeneration-Inducing Medicine™’ Bone marrow mesenchymal stem cells mobilized into the peripheral blood stream induce the tissue regeneration. ia#e : Damaged site Administration of “Regeneration- hide Inducing Medicine™” r Chemokines produced in I } necrotic tissue f (e.g. SD
Slide 11: Discovery of in-vivo mechanism inducing tissue regeneration
Discovery of in-vivo mechanism inducing tissue regeneration -Differences between normal skin and epidermolysis bullosa skin In normal skin (Figure A), type 7 collagen functions like an adhesive, bonding the epidermis and dermis, the superficial layers of skin. In epidermolysis bullosa congenita (Fig
Slide 12: Discovery of in-vivo mechanism inducing tissue regeneration
Discovery of in-vivo mechanism inducing tissue regeneration The beginning of the research and development on “Regeneration-Inducing Medicine Hypothesis of stem cell recruitment mechanism from bone marrow to damaged skin. Necrotic epidermis with {Despite loss of epidermal stem >. blood flow disrupted
Slide 13: Discovery of in-vivo mechanism inducing tissue regeneration
of in-vivo mechanism inducing tissue regeneration Discovery of crosstalk mechanism between damaged skin and bone marrow mesenchymal stem cells via necrotic tissue-derived factor Necrosis of epidermal cells Peeled epidermis ’ > Cytoplasm / Epidermal cells oe ms Nucleus | Accumulation of intravascular
Slide 14: HMGB1 peptide drugs with improved safety
HMGB1 peptide drugs with improved safety Designing highly safe, chemically synthesized peptide drug from A-Box domain of HMGB1 protein HMGB1 protein © An Important in vivo molecule that activate tissue regeneration Katsuto Tamai Representative Director , Chairman, CSO Identifying the function of pro
Slide 15: 3. Advantages of Regeneration-Inducing Medicine
3. Advantages of r “Regeneration-Inducing Medicine™
Slide 16: Advantages: Epidermis formation during human development
TM93 Advantages of “Regeneration-Inducing Medicine Epidermis formation during human development Carnegie developmental stage (developmental stage of vertebrate embryos) fertilized eggs diy CS9*: Embryo section (ectoderm) epidermis 2-cell blastodermic vesicle » (inner cell mass > ES ae =m i> ee) ee a
Slide 17: Advantages of Regeneration-Inducing Medicine
Advantages of “Regeneration-Inducing Medicine™” Ectodermal mesenchymal stem cells have high pluripotency and differentiation ability to various tissues. Tissues into which differentiation has been confirmed in our collaborative research with Osaka University Tissues into which differentiation is tho
Slide 18: Expanding Indications and Markets (Number of patients)
Expanding Indications and Markets (Number of patients) Targeting all areas where mesenchymal stem cell WB : Clinical trial on going therapy can be effective Other countries and regions Cardiomyopathy r Traumatic brain injury 121K in US in — 13.5M in US Cerebral infarction Tt i Traumatic brain injury
Slide 19: Functions of mesenchymal stem cells
Functions of mesenchymal stem cells In-vivo mesenchymal stem cells have 5 distinctive capabilities 1. Cell migration ability 3. Trophic factor secretion ability Mesenchymal stem cells migrate to damaged tissue via the bloodstream Promotes cell proliferation and tissue repair by secreting growth fact
Slide 20: In vitro culture reduces the functions of MSCs
In vitro culture reduces the functions of MSCs iy “Regeneration-Inducing Medicine Manufacturing process of conventional cellular medicine Mesenchymal stem cells ys ra N € Autologous transplantation in vitro culture Allogeneic | = transplantation _ Mesenchymal stem cells lose their functions during i
Slide 21: Advantages in global expansion
TM393 Advantages of “Regeneration-Inducing Medicine “Regeneration-Inducing Medicine™” products have an advantage over conventional regenerative medicine products in terms of global expansion Issues in the Global Development of Regenerative Medicine Products Using Living Cells @ Need for mass culture
Slide 22: Summary of advantages vs cell therapy and chemicals
Summary of advantages of “Regeneration-Inducing Medicine “Regeneration-Inducing Medicine “Regeneration-Inducing Medicine™” Cell therapy TM93 includes advantages in both cell therapy and chemicals Chemicals O Applicable for large-scale tissue damage Applicable for large tissue damage with large numbe
Slide 23: Solving four major problems of conventional cell therapy
TM93 Summary of advantages of “Regeneration-Inducing Medicine “Regeneration-Inducing Medicine™” can solve the four major problems of conventional cell therapy Cancerization risk Risk of cancer depending on the site of gene insertion iPS cell = ; ; Somatic ES cell a “Regeneration-Inducing is) stem ce
Slide 24: Summary of advantages: technology platform
Summary of advantages of “Regeneration-Inducing Medicine™” The “Regeneration-Inducing Medicine™” technology platform aims to be a game-changer in the field of cell therapy. 7 O2 stemriM of ectodermal Aiming to change the common mesenchymal Effective understanding of cell therapy. stem cells into acc
Slide 25: 4. Business Areas and Pipeline Progress Status
4. Business Areas and Pipeline Progress Status
Slide 26: Overview of Development Pipeline
Overview of Development Pipeline B © QQ | APR AR | bh Projectcode | Development candidate Indication Investigator Research | Pre-clinical | Phase 1 Phase2 | Phase Status a 2022.07 Add Phase2 Start = Shionogi & Co. Add 2024.02 Add Phase2 FPI Epidermolysis Ltd Phase2 2025.06 Add Phase2 LPI bullosa 202
Slide 27: Pipeline Progress (as of October 2026)
HFENTIS1 VICHIFS 1 FHO EK, Progress {as of October 2026) (Reference) From "Presentation Material for Business Plan and Growth Potential ” disclosed on October 31, 2025 Additional Phase 2 Receipt of Study Results Additional Phase 2 trial currently underway Receipt of Global Phase 2b Study Results Glo
Slide 28: Redasemtide: Additional Phase Trial for DEB
Redasemtide: Additional Phase 2 Trial for DEB Ad nal Phase 2 Protocol Study objectives Evaluation of efficacy and safety of Redasemtide in patients Clinical Trial Timeline to Date with dystrophic epidermolysis bullosa having intractable ulcers December 2017: Initiation of Phase 2 investigator-initia
Slide 29: Receipt of Additional Phase Study Results in DEB
Receipt of Additional Phase 2 Study Results for Redasemtide in Dystrophic Epidermolysis Bullosa Primary endpoint | Closure of intractable ulcer | Clinical Findings Favorable Clinical Outcomes, Including Reduction in Total Ulcer Area, Were Observed in Some Patients 3 of 4 cases Achieved | Safety and
Slide 30: Redasemtide: Global Phase 2b Trial for Acute Ischemic Stroke
Redasemtide: Global Phase 2b Trial for Acute Ischemic Stroke Developing a stroke treatment that alleviates time constraints compared to conventional therapies. eeatellschemie SUEKS Market Size in Japan 187 thousand people Mechanism of action Suppression of inflammation Promotion of angiogenesis and
Slide 31: Redasemtide: Global Phase 2b Trial for AIS
Redasemtide: Global Phase 2b Trial for AIS Phase 2b Trial Protocol (After interim analysis) Study objectives Evaluation of the Efficacy, Safety, and Tolerability of Redasemtide in Patients with Acute Ischemic Stroke + . Patients aged 18 years or older who can receive treatment within 25 hours of str
Slide 32: Receipt of Global Phase 2b Study Results in Stroke
Receipt of Global Phase 2b Study Results for Redasemtide in Acute Ischemic Stroke Primary endpoint | Modified Rankin Scale (mRS) at 90 Days After Initial Dosing Compared with Placebo No Statistically Significant Difference Cohort Without Endovascular Recanalization Therapy Primary Endpoint Not Met |
Slide 33: Phase II Trial for Ischemic Cardiomyopathy
Redasemtide: Phase II Investigator-Initiated Clinical Trial for Ischemic Cardiomyopathy Evaluate the efficacy and safety of Redasemtide Patients with ischemic cardiomyopathy who have undergone coronary artery bypass grafting (CABG). | Multicenter, randomized, placebo-controlled, double-blind study.
Slide 34: Redasemtide: Osteoarthritis of the Knee
Redasemtide: Osteoarthritis of the Knee Developing a treatment for osteoarthritis of the knee that does not rely on surgical interventions. Osteoarthritis of the Knee(OA) thigh peroneal pue sayeid ym Buna smais Market size in Japan *Number of patients with symptoms: approximately 8 million +Estimate
Slide 35: Redasemtide: Osteoarthritis of the Knee
Redasemtide: Osteoarthritis of the Knee Study | objectives Subject population Study design Intervention Regimen Primary endpoint Secondary endpoint Evaluation of efficacy and safety of Redasemtide in patients with Osteoarthritis (OA) of the knee Patients with knee OA who have undergone high tibial o
Slide 36: Redasemtide: Chronic Liver Disease
Redasemtide: Chronic Liver Disease Developing a treatment for chronic liver disease that works by inhibiting fibrosis. hi iver Disease (CLD Healthy Chronic Liver Disease Pathe: Scout Spal Approximately 400,000 to 500,000 people Fibrosis Mechanism of action P ‘ progresses due § Supply of " ‘ to lalar
Slide 37: Redasemtide: Chronic Liver Disease
Redasemtide: Chronic Liver Disease Main purpose Clinical trial design Target patient Administration group/number of cases Endpoint Site Pre-observation period (3 months) Evaluate the safety and exploratory efficacy in patients with chronic liver disease Single arm study, Open label, Uncontrolled Pat
Slide 38: TRIM5: Novel Regeneration-Inducing Peptide for Local Administration
TRIM5:Novel Regeneration-Inducing Peptide for Local Administration Developing protein drugs that accumulate mesenchymal stem cells at the site of injury Small injury Efficient accumulation of mesenchymal stem cells by topical Large injury or chronic phase administration of TRIMS * SDF1-ais released,
Slide 39: SR-GT1: Stem cell gene therapy
SR-GT1:Stem cell gene therapy Aim to cure intractable genetic disease by stem cell gene therapy Concept Ex vivo gene therapy involving the introduction of correct type VII collagen gene into autologous mesenchymal stem cells (MSCs) and administration of the cells in the blisters of the patient. Mini
Slide 40: SR-GT1: Ex vivo gene therapy comparison
SR-GT1:Stem cell gene therapy Ex vivo gene therapy with minimal invasiveness, high efficacy, and persistent effect This therapy employs a novel method of isolating Bf-MSCs from a patient, efficient delivery of functional type VII collagen gene to the cells, and novel administration method to the pat
Slide 41: Therapeutic efficacy and duration in RDEB model mice
Verification of therapeutic efficacy and duration of drug effect of this treatment using RDEB model mice = Restoration of the type-VIl collagen protein (C7) at the basement membrane on RDEB model mouse * poral aes Skin tissue of RDEB model mouse after administration Lentiviral vector x Non-treat Tre
Slide 42: SR-GT1: Therapeutic effects on RDEB skin model
SR-GT1:Stem cell gene therapy Therapeutic effects on RDEB skin model m= We confirmed the effect of gene therapy using patient-derived Bf-MSCs by RDEB skin model and artificially forming blisters by suction method. , RDEB skin equivalents RBEB ship ecuiveledre with gene transduced Bf-MSCs Negative pr
Slide 43: 5. Future Growth Strategy
5. Future Growth Strategy
Slide 44: Future Growth Strategy
Future Growth Strategy Growth Strategy to Maximize the Potential Value of “Regeneration-Inducing Medicine Out-Licensing of Next-Generation Regeneration-Inducing Medicine Support for the development of Redasemtide. The clinical development of stem cell gene therapy (SR-GT1) Expansion of the developme
Slide 45: TRIM3, TRIM4
TRIM3, TRIM4 We have identified several peptides that mobilize mesenchymal stem cells from the bone marrow into the bloodstream, accumulate in damaged tissues, and induce functional regeneration. Among them, two peptides with particularly prominent activity have been selected as candidates for the n
Slide 46: Out-licensing negotiations at conferences
Continuing from last year, out-licensing negotiations were conducted with multiple pharmaceutical companies both domestically and internationally. » - Rg ; “> J Siem Se 2025.10.8~10 @Yokohama, JPN p J.P.Morgan Healthcare Conference — 2026.1.12~15 @San Francisco, CA | ? | oh 8g international e”’ Conv
Slide 47: IP Strategy
IP Strategy Patents related to “Regeneration-Inducing Medicine™” have been granted in various countries. We are steadily promoting the intellectual property protection of our research outcomes, paving the way for global expansion. Patent Grant Status Russia 1 2 1 ay 6 cases cases 2 pend ‘orea Total
Slide 48: IP Strategy
IP Strategy During the fiscal year ended July 2026, patents related to Regeneration-Inducing Medicine™ were granted in multiple countries. Steady progress was made in securing intellectual property rights for research achievements. (Based on timely disclosures issued between August 2025 and July 202
Slide 49: StemRIM Institute of Regeneration-Inducing Medicine
Stem RIM StemRIM Institute of Regeneration-Inducing Medicine In June 2020, StemRIM Institute of Regeneration-Inducing Medicine, Osaka University (covering an area of 1,540 square meters) was established on the 6th and 7th floors of the Techno Alliance Building at Osaka University's Suita Campus. Pro
Slide 50: Development schedule
NAFSA UF Given the long development timeline for pharmaceuticals, a pipeline development plan is formulated based on a long-term management vision. Cyrrent Development Schedule ‘Add Phase? Receipt of Study Results Epidermolysis Additional P2 Study y, Application bullosa Receipt of Study Results 1 2
Slide 51: Forecast for the fiscal year ending July 2027
Forecast for the fiscal year ending July 2027 Research Development Progress for Fiscal Year Ended July 2026 Previous Disclosure (October 31, 2025) +———_, Actual Results Research Progress Outlook for the Fiscal Year Ending July 2026 Research Progress Results for the Fiscal Year Ended July 2026 Resear
Slide 52: Allocation Status of Raised Funds
Allocation Status of Raised Funds Funding Method Stock issuance associated with new listing (August 2019) Amount Raised Use of Funds Funds for the establishment and maintenance of the “Regeneration-Inducing MedicineTM” research institute and an animal testing facility. Planned Disbursement Amount(Ti
Slide 53: 6. Risk Information
6. Risk Information
Slide 54: Risk Information
Risk Information Possibility and Timing of Countermeasures Materialization A) Uncertainty in the +Risk of development delays or discontinuation due to the inability to Medium / As -We aim to maintain multiple pipelines in development of the discover beneficial effects in clinical trials. needed clin
Slide 55: Appendix
Appendix
Slide 56: Management Team
Management Team Representative Director, Chairman & CSO Katsuto Tamai Representative Director, Chairman(Sep. 2026—Present) Director, StemRIM Inc. (Oct. 2022) Guest Professor, Endowed course of Regeneration-Inducing Medicine Graduate School of Medicine/ Faculty of Medicine, The University of Osaka (O
Slide 57: Corporate Information
Corporate Information Corporate Name Chief Executives Established Business Description Shareholders’ Equity Equity Ratio Number of Employees StemRIM Inc. Masatsune Okajima (Representative Director) October 30, 2006 Research and Development of “Regeneration Inducing-Medicine" 4,161 million yen 70.3 %
Slide 58: Disclaimer
Disclaimer This document is based on economic, regulatory, market, and other conditions as of its publication date, and neither the company nor its representatives guarantee the accuracy or completeness of the information contained herein. The information may change without prior notice, and such ch